<DOC>
	<DOCNO>NCT01698723</DOCNO>
	<brief_summary>The term Acute chronic liver failure ( ACLF ) describe clinical entity characterize acute rapid deterioration liver function patient previously well-compensated liver disease owe effect precipitate event . In condition two insult act simultaneously , one preexisting liver injury ( chronic liver disease ) acute injury responsible acute decompensation . HEV major factor responsible clinical entity high mortality rate . Ribavirin safe drug show inhibit replication HEV , important drug treatment patient . Therefore present study design study impact Ribavirin reduce mortality due HEV relate ACLF .</brief_summary>
	<brief_title>A Trial Ribavirin Patients With ACLF Due Hepatitis E Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>All ACLF due HEV Consent participate trial collection blood . Pregnant nursing mother . Severe anemia Other etiology ACLF ( eg . Alcohol , drug , reactivation hepatitis B hepatitis C , variceal bleeding , surgical intervention sepsis ) Hepatocellular carcinoma ( HCC ) Hepatorenal syndrome ( HRS ) admission Presence life threaten cardiovascular , respiratory neurological disease Acquired Immunodeficiency Syndrome Patients hemoglobinopathy ( e.g. , thalassemia major , sicklecell anemia ) Refusal provide consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>ACLF</keyword>
	<keyword>HEV</keyword>
	<keyword>Ribavirin</keyword>
</DOC>